Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07738159) titled 'Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma' on July 25.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: West China Hospital
Condition:
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
QL1706
Lenvatinib
Chemotherapy
Intervention:
Drug: Iparomlimab and tuvonralimab injection (QL1706) + Lenvatinib + EP/EC
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 1, 2026
Target Sample ...